Loading
Inventiva Stock: price and insider trades · France
No insider purchase over the last 90 days. The latest was filed 24 Oct 2025.
Inventiva: what insiders have been doing
Inventiva, classified in the Healthcare & Pharma sector, is a listed company based in Daix, France. Its insiders report their share dealings to AMF. 11 insiders have disclosed 14 filings since 18 October 2025.
Not one open-market sale was filed. On the buying side, 1 insider reported 1 purchase totalling €81k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. On the buying side, the filings list 1 board member among the declarants. The largest single trade was a purchase of €81k by Renee Aguiar Lucander, published on 24 October 2025.
The latest purchase dates back some time: it was published 358 days ago, on 24 October 2025. Filings reach the AMF feed a median of 4 days after the trade. The regulation allows three business days to notify a trade (MAR article 19).
Across the 316 companies tracked on its exchange, the median is 6 filings; at 14 filings, this issuer sits above that mark. Over the whole record (from 2021), the tally stands at 2 purchases and 1 sale.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. This summary is built from AMF disclosures alone and does not predict where the share price will go.
Key facts
Headquarters: Daix, France
Source: Wikidata (CC0).
Insider Decl.
35
Thresholds
n/a
Buy Volume
€2M
2 ops. · all time
Sell Volume
€54,568
1 ops. · all time
Who traded when
BuySaleRenee Aguiar Lucander1 buy
Analyst consensus: bullish or bearish?
Analysts rate Inventiva Strong Buy (bullish), based on 4 analysts. Average price target: €9.77.
Financial data
as of FY 2025FY ended December 2025 · cache
€2.65
Analyst consensus
4 analystsStrong buy
€6.60Target €9.77(+269%)€15.48
Income statement
Revenue€4.5M
EBITDA-€317.3M-7078% margin
Net income-€354.1M-7899.6% margin
Valuation
PER (forward)-4.4x
P/Book10.6x
Beta1.00
Balance sheet & cash
Market cap€624.8M
Total debt€59.9M
Free Cash Flow-€105.1M
Debt / Equity235%
Profitability & ownership
ROE-989.1%
ROA-42.7%
% insiders12.6%
% institutions50.3%
Last declaration on 12 October 2026
Declarations35 total
87,500 shares0Option d'achatHors plateforme de négociationISIN FR00132330122026DD1143658
75,000 shares0ActionHors plateforme de négociationISIN FR00132330122026DD1141065
50,000 shares@ €0.680.4% of flowBon de souscription en actionHors plateforme de négociationISIN FR00132330122026DD1135766
50,000 shares@ €0.68100.0% of flowBon de souscription en actionHors plateforme de négociationISIN FR00132330122026DD1135748
50,000 shares@ €0.68100.0% of flowBon de souscription en actionHors plateforme de négociationISIN FR00132330122026DD1135758
50,000 shares@ €0.68100.0% of flowBon de souscription en actionHors plateforme de négociationISIN FR00132330122026DD1135739
50,000 shares@ €0.68100.0% of flowBon de souscription en actionHors plateforme de négociationISIN FR00132330122026DD1135730
25,000 shares0ActionHors plateforme de négociationISIN FR00132330122026DD1088249
25,000 shares0ActionHors plateforme de négociationISIN FR00132330122026DD1088082
50,000 shares0ActionHors plateforme de négociationISIN FR00132330122026DD1088084
25,000 shares0ActionHors plateforme de négociationISIN FR00132330122026DD1088088
24,997 shares0Option d'achatHors plateforme de négociationISIN FR00132330122025DD1085948
321,031 shares@ €0.010.0% of flowExercice de Bons de Souscriptions à ActionsHors plateforme de négociationISIN FR00132330122025DD1067004
24,700 shares@ €3.2947100.0% of flowActionEuronext ParisISIN FR00132330122025DD1065222
Canonical exit: 22 Jan 2026 (T+90)
6,637,037 shares@ €1.3599.6% of flowSouscription d'Actions à Bons de Souscription d'ActionsEuronext ParisISIN FR00132330122025DD1037069
60,000 shares0ActionHors plateforme de négociationISIN FR00132330122024DD1012782
30,000 shares0ActionHors plateforme de négociationISIN FR00132330122024DD1012786
30,000 shares0ActionHors plateforme de négociationISIN FR00132330122024DD1012789
30,000 shares0ActionHors plateforme de négociationISIN FR00132330122024DD1012792
30,000 shares0ActionHors plateforme de négociationISIN FR00132330122024DD1012781
21,500 shares0ActionHors plateforme de négociationISIN FR00132330122024DD959506
10,750 shares0ActionHors plateforme de négociationISIN FR00132330122024DD959511
14,333 shares0ActionHors plateforme de négociationISIN FR00132330122024DD959517
21,500 shares0ActionHors plateforme de négociationISIN FR00132330122024DD959501
21,500 shares0ActionHors plateforme de négociationISIN FR00132330122024DD959502
25 of 35 declarations
About Inventiva
Inventiva is a French clinical-stage biopharmaceutical company listed under ISIN FR0013233012 and headquartered in Daix, Burgundy, France. Founded in 2011 by former executives of the French subsidiary of Solvay, the company began operating in 2012 after acquiring an integrated R&D platform. Its scientific roots are closely linked to legacy assets and expertise inherited from Abbott, Solvay and Fournier, which helped establish an internal research base focused on small-molecule drug discovery. Over time, Inventiva positioned itself as a specialist in orally administered therapies for diseases with high unmet medical need, initially spanning fibrosis, lysosomal storage disorders and oncology.
Inventiva’s current strategy is highly concentrated on lanifibranor, its lead product candidate, which is being evaluated in the pivotal Phase 3 NATiV3 trial for the treatment of MASH (metabolic dysfunction-associated steatohepatitis) with advanced fibrosis. MASH is a progressive liver disease associated with metabolic dysfunction and can lead to cirrhosis and liver-related complications. Lanifibranor is designed as a pan-PPAR modulator targeting key disease pathways: steatosis, inflammation and fibrosis. The company reported positive Phase 2b data showing statistically significant efficacy on key regulatory endpoints, together with a favorable safety profile, which supported FDA Breakthrough Therapy Designation. These data underpin Inventiva’s ambition to deliver a differentiated oral therapeutic option in a large and still underserved market.
Read moreShow less
Historically, Inventiva pursued a broader pipeline, including programs in rare diseases such as mucopolysaccharidoses, as well as earlier-stage oncology and fibrosis assets. However, the company has recently sharpened its strategic focus and streamlined resources toward lanifibranor to maximize the probability of success and preserve capital. This refocusing came alongside operational reorganization and financing actions, reflecting the capital-intensive nature of late-stage biotech development.
Geographically, Inventiva is a French company with international reach. Its clinical programs have been developed through a broad network of trial sites, including the United States, Europe and selected Asian markets, and the company has maintained visibility in both Euronext and U.S. investor circles. Notable facts include its transition from a diversified pipeline to a single-asset focus, its advanced clinical status, and the fact that it remains one of the more closely watched French biotech names in the metabolic-liver disease space. Inventiva’s investment case is therefore closely tied to clinical execution, regulatory milestones and the eventual commercial potential of lanifibranor.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
